Business Context and Reporting Period
Company: Henry Schein, Inc. (HSIC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 28, 2024 (Q3 2024)
Business Overview: Henry Schein is a global provider of health care products and services to office-based dental and medical practitioners. Operations are conducted through two reportable segments: Health Care Distribution and Technology and Value-Added Services.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Net Sales | $3,174 million | $3,162 million | $9,482 million | $9,322 million |
| Gross Profit | $993 million | $995 million | $3,023 million | $2,936 million |
| Gross Margin | 31.3% | 31.5% | 31.9% | 31.5% |
| Operating Income | $157 million | $200 million | $466 million | $576 million |
| Net Income (Attributable to HSIC) | $99 million | $137 million | $296 million | $398 million |
| Diluted EPS | $0.78 | $1.05 | $2.30 | $3.02 |
| Operating Cash Flow (9M) | $644 million | $532 million | - | - |
| Total Debt | $2,653 million | $2,351 million | - | - |
| Cash & Equivalents | $126 million | $171 million | - | - |
Material Changes vs. Prior Period
- Revenue: Q3 2024 net sales increased 0.4% year-over-year. The 9-month period saw a 1.7% increase. Growth was driven by acquisitions and the Technology segment, partially offset by a slower recovery from the October 2023 cyber incident and lower sales of PPE and COVID-19 test kits.
- Profitability: Operating income decreased 21.5% in Q3 and 19.1% for the 9-month period compared to the prior year. This decline was primarily due to increased restructuring costs and higher operating expenses.
- Restructuring: The company recorded $48 million in restructuring costs for Q3 2024 (vs. $11 million in Q3 2023). This includes $36 million related to a new "2024 Plan" initiated in August to integrate acquisitions and right-size operations, and $12 million related to the completion of the "2022 Plan."
- Interest Expense: Interest expense increased significantly (31.9% in Q3, 64.7% for 9M) due to higher interest rates and increased borrowings.
- Acquisitions: Significant activity includes the acquisition of TriMed Inc. (60% interest) in April 2024 and Shield Healthcare (90% interest) in late 2023, which contributed to sales growth in the Medical segment.
Guidance, Outlook, Risks, and Unusual Items
- Cyber Incident Impact: The October 2023 cyber incident continues to impact sales, particularly among episodic customers. The company incurred $1 million in Q3 and $9 million in 9M 2024 in direct expenses, partially offset by $10 million (Q3) and $20 million (9M) in insurance proceeds. A class action settlement regarding the incident was preliminarily approved for $2.9 million.
- Restructuring Outlook: The company expects to record additional restructuring charges associated with the 2024 Plan in Q4 2024 and 2025, though specific amounts have not been determined.
- Share Repurchases: The Board authorized an additional $500 million for share repurchases in July 2024. As of September 28, 2024, $455 million remains available under the program.
- Tax Rate: The effective tax rate for the 9 months ended September 28, 2024, was 25.1%, compared to 22.5% in the prior year, primarily due to state/foreign taxes and interest expense. The impact of OECD Pillar Two global minimum tax rules was deemed immaterial as of the reporting date.
- Legal Proceedings: The company is a defendant in multiple opioid-related lawsuits and a False Claims Act lawsuit regarding "Buy American" laws (settled for an immaterial amount). Management does not anticipate a material adverse effect from pending matters.
Investor Verification Checklist
- Cyber Incident Recovery: Verify the pace of sales recovery from the October 2023 cyber incident, specifically regarding episodic customers and the impact on working capital cycles.
- Restructuring Costs: Monitor the total cost and timeline of the new 2024 restructuring plan, as future charges are expected in Q4 2024 and 2025.
- Debt Servicing: Assess the impact of rising interest rates on future interest expense, given the increase in total debt to $2.65 billion.
- Acquisition Integration: Evaluate the integration progress and financial contribution of recent acquisitions (TriMed, Shield Healthcare) to offset organic headwinds.
- Legal Exposure: Track the status of the opioid litigation and the final court approval of the $2.9 million cyber incident class action settlement.